Evaxion A/S (NASDAQ: EVAX) convenes 2026 Annual General Meeting in Denmark

Rhea-AI Filing Summary

Evaxion A/S filed a Form 6-K to furnish a press release convening its Annual General Meeting. The meeting will be held on April 16, 2026 at 14:00 CET at the company’s offices in Hørsholm, Denmark. Shareholders can access the agenda, proposals and related materials on Evaxion’s website.

The company describes itself as a clinical-stage TechBio business using its AI-Immunology™ platform to develop novel vaccine candidates for cancer and infectious diseases, and includes standard forward-looking statement language outlining key business and financial risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 03/19/2026 - 09:10 AM Learn about SEC filing dates

FAQ

What did Evaxion A/S (EVAX) disclose in its latest Form 6-K?

Evaxion A/S disclosed that it has convened its Annual General Meeting for April 16, 2026. The filing furnishes a press release with meeting details and incorporates the information by reference into several existing SEC registration statements.

When and where is Evaxion A/S (EVAX) holding its 2026 Annual General Meeting?

Evaxion’s 2026 Annual General Meeting is scheduled for April 16, 2026 at 14:00 CET. It will take place at the company’s offices at Dr. Neergaards Vej 5F, 2970 Hørsholm, Denmark, as stated in the notice.

Where can Evaxion (EVAX) shareholders find the AGM agenda and proposals?

Shareholders can find the AGM agenda, proposals and related materials on Evaxion’s website. The notice directs investors to www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/ for access to the detailed documentation for the April 16, 2026 meeting.

What type of company is Evaxion A/S (EVAX) according to the filing?

Evaxion describes itself as a clinical-stage TechBio company built on its AI-Immunology™ platform. The platform uses artificial intelligence to decode the human immune system and support development of novel vaccine candidates for cancer and infectious diseases.

Which SEC registration statements incorporate this Evaxion Form 6-K by reference?

The Form 6-K is deemed incorporated by reference into Evaxion’s registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files. This means the AGM notice information becomes part of those existing SEC registration materials.

Does Evaxion’s announcement include forward-looking statements and risk factors?

Yes. The announcement contains forward-looking statements identified by terms like “believe,” “expect,” and “plan.” It highlights risks related to financial condition, development activities, regulation, partnerships, intellectual property, and macroeconomic factors, referencing the latest Form 20-F for detailed risk factors.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On March 19, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Notice to convene Evaxion’s Annual General Meeting". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Notice to convene Evaxion’s Annual General Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: March 19, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Notice to convene Evaxion’s Annual General Meeting

COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.

The meeting will be held at the company’s offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.

The agenda and proposals can be found on Evaxion’s website, along with other materials:
www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 4.8 KB